| FDG PET/CT in monitoring response to treatment in gynecological malignancies. | |
| | |
MedLine Citation:
|
PMID: 23299090 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: To evaluate the role of fluorodeoxyglucose (FDG) PET/CT as cancer response testing in gynecological malignancies. RECENT FINDINGS: The application of FDG PET/CT in patients with endometrial and ovarian cancer to evaluate treatment response was found to have no clinical benefits.Patients with cervical cancer seem to benefit from the use of PET/CT in estimation of treatment response. The influence of different treatments on FDG uptake, timing, frequency of examination, and survival advantage are evaluated and discussed. SUMMARY: Growing evidence supports an important role for functional imaging FDG PET/CT as a monitoring tool in patients with uterine-cervix carcinoma. Further studies are needed to establish the clinical benefits of this modality in this population. |
| | |
Authors:
|
Amnon Amit; Orit Person; Zohar Keidar |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current opinion in obstetrics & gynecology Volume: 25 ISSN: 1473-656X ISO Abbreviation: Curr. Opin. Obstet. Gynecol. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007264 Medline TA: Curr Opin Obstet Gynecol Country: England |
Other Details:
|
Languages: eng Pagination: 17-22 Citation Subset: IM |
Affiliation:
|
aDepartment of Obstetrics and Gynecology, Gynecologic Oncology Unit bOncology Institution cDepartment of Nuclear Medicine, Rambam Healthcare Campus, Haifa, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary human papillomavirus testing in organized cervical screening.
Next Document: Perioperative care in gynecologic oncology.